Loading...

NSPR

NN

INSPIRA TECHNOLOGIES OXY BHN LTD

(IINN)

2026 6-K

Equity Facilities Termination

31 Mar '26

Company Update

26 Mar '26

New Subsidiary Established

26 Mar '26

Debenture Amendment

25 Feb '26

Expansion Announcement

18 Feb '26

Sales Agreement Executed

17 Feb '26

Nasdaq Notification

12 Feb '26

Vendor Approval Secured

9 Feb '26

Funding Agreement

6 Feb '26

New Blood Sensor

3 Feb '26

Clinical Evaluation Success

29 Jan '26

Government Validation Progress

21 Jan '26

Acquisition Announcement

13 Jan '26

Strategic Vision Update

8 Jan '26

Acquisition Announcement

5 Jan '26

General Meeting Held

31 Dec '25

Purchase Order Confirmation

23 Dec '25

Equity Financing Announcement

15 Dec '25

Patent Granted

9 Dec '25

Lab Capabilities Update

3 Dec '25

Meeting Notice Filed

25 Nov '25

Clinical Study Completion

13 Nov '25

Regulatory Update

6 Nov '25

Strategic Alliance

22 Oct '25

Management Change

21 Oct '25

Financial Update

1 Oct '25

New Sensor Announcement

18 Sep '25

Share Offering Update

16 Sep '25

FDA Submission Update

11 Sep '25

Hospital Adoption Update

2 Sep '25

Patent Approval Received

22 Aug '25

Government Order Secured

19 Aug '25

Consulting Firm Activation

31 Jul '25

Compliance Regained

18 Jul '25

Director Resignation

17 Jul '25

Government Talks Success

10 Jul '25

Government Talks Update

7 Jul '25

Major Purchase Order

2 Jul '25

Share Offering Increase

1 Jul '25

Shareholder Meeting

23 Jun '25

Clinical Interest Growth

11 Jun '25

Production Expansion

5 Jun '25

Shareholder Meeting Notice

30 May '25

Global Rollout Initiated

29 May '25

Executive Team Update

27 May '25

Shareholder Approval

12 May '25

FDA Approval Announcement

7 May '25

Gas Exchange Efficiency

23 Apr '25

First Revenue Generated

15 Apr '25

Capital Increase Filed

10 Apr '25

Shareholders Meeting

7 Apr '25

Patient Treatment Success

7 Apr '25

Successful Installation

25 Mar '25

Sales Agreement Signed

14 Mar '25

CEO Update Released

14 Mar '25

Nasdaq Notification

13 Mar '25

Financial Results Report

11 Mar '25

Clinical Study Results

4 Mar '25

Positive Results

11 Feb '25

Strategic Position Update

10 Feb '25

New Product Integration

5 Feb '25

Product Launch Update

27 Jan '25

Board Changes

21 Jan '25

Partnership Announcement

17 Jan '25

New Technology Unveiled

14 Jan '25

Production Response

10 Jan '25

Event Showcase Announcement

7 Jan '25

Annual Meeting Results

30 Dec '24

Private Placement Announcement

27 Dec '24

Systems Delivery Announcement

16 Dec '24

Technology Expansion

10 Dec '24

New Collaboration

4 Dec '24

Shareholder Meeting Notice

25 Nov '24

Investor Presentation

12 Nov '24

New Facility Announcement

24 Oct '24

New Product Announcement

9 Oct '24

Patent Approval Secured

13 Sep '24

Clinical Results Announcement

28 Aug '24

FDA Approval Announcement

22 Aug '24

Interim Financial Report

15 Aug '24

Product Evaluation Update

13 Aug '24

Product Launch Announcement

30 Jul '24

Regulatory Approval

11 Jul '24

Business Plan Announcement

20 Jun '24

Amended Filing

18 Jun '24

Share Issuance Agreement

17 Jun '24

Purchase Order Granted

13 Jun '24

FDA Clearance Achieved

28 May '24

Product Launch

2 May '24

Certification Received

25 Apr '24

Press Release Summary

17 Apr '24

Bacterial Growth Prevention

10 Apr '24

Shareholder Meeting Approval

9 Apr '24

Artificial Womb Program

3 Apr '24

Share Offering Announcement

1 Apr '24

Financial Results Report

25 Mar '24

Regulatory Submission

18 Mar '24

New Technology Data

12 Mar '24

Extraordinary Meeting Notice

8 Mar '24

Extraordinary Meeting Notice

4 Mar '24

Research Announcement

4 Mar '24

FDA Approval Update

27 Feb '24

New Platform Introduction

22 Feb '24

Patent Approval

14 Feb '24

New Collaboration

8 Feb '24

Strategic Agreement

30 Jan '24

New Product Announcement

9 Jan '24

New Partnership Agreement

2 Jan '24

External Links:

SEC

On January 5, 2026, Inspira Technologies OXY B.H.N. Ltd signed a term sheet to acquire a Target’s liquid biopsy business for 40% of its share capital and received a $15 million equity investment at a $180 million valuation. This deal includes a $1 million senior convertible debenture agreement with the Target and contingent value rights for existing shareholders related to the sale of company assets.

AI Assistant

INSPIRA TECHNOLOGIES OXY BHN LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.